ArticleRenal failure2025
Genetic and metabolomic pathways linking frailty, chronic kidney disease, and kidney failure: a Mendelian randomization and multi-omics analysis.
Article in Renal failure, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Global population aging highlights frailty as a critical health concern, yet its genetic basis remains poorly understood. We employed Mendelian randomization (MR) and National Health and Nutrition Examination Survey (NHANES) to examine causal relationships between frailty index (FI) and 36 urological diseases, investigating shared genetic mechanisms. The FI was calculated using genome-wide association data, and bidirectional MR analysis with multiple statistical methods was applied to investigate causal links between FI and 36 urological diseases. Complementary observational analyses using NHANES and generalized summary MR validation were conducted, followed by genetic correlation assessments, genome annotation, and metabolomic explorations to identify mediating pathways. MR analysis identified a significant causal association between FI and renal tubule-interstitial disease, chronic kidney diseases (CKDs), diabetes with renal complications, renal failure, and acute kidney injury. Reverse MR analysis indicated a bidirectional causal relationship between FI and acute renal failure, as well as CKD and type 1 diabetic kidney disease. NHANES data confirmed FI as an independent risk factor for CKD and renal failure. Genetic linkage analyses identified strong regional correlations between FI and CKD/renal failure within the chromosome 6 locus (31,571,218-32,682,664). Genome-wide analyses uncovered 103 novel single-nucleotide polymorphism with pleiotropic effects on the frailty-urinary disease relationship. Mediation analyses implicated the complement pathway (C2), SLITRK1, and 4-methylhexanoylglutamine as putative mediators of FI effects on CKD and kidney failure. This study elucidates the bidirectional causal relationship between frailty and CKD, while identifying novel genetic variants and metabolic pathways. These findings provide a molecular basis for developing personalized therapeutic strategies targeting both frailty and urological disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.